Kornimate/medical-research-clean huggingface dataset:
exodof: robotic exoskeleton for upper limb motor rehabilitation after stroke

Conditions: Stroke

Summary: two decades ago, the projection of recovery of the upper extremity (ue) after a stroke had a very poor prognosis worldwide. nowadays, thanks to medical advances and early rehabilitation, the prognosis for recovery has improved; however, there is still a limit that no therapy has been able to overcome, related to spontaneous recovery as part of the natural evolution of the pathophysiological process, rather than with the contribution of rehabilitation. additionally, existing therapies show partial effectiveness on the recovery of ue function, but do not avoid the use of compensatory strategies or alternatives to normal movement. given this situation, there is an active search for new therapeutic approaches. in this clinical trial the investigators propose a rehabilitation paradigm that promotes the recovery of control of specific planes of movement through the selective restriction of degrees of freedom, simplifying control demands. the investigators sought to test the hypothesis that people with stroke in the early subacute stage and who present alterations in the movement of the upper extremity, a rehabilitation protocol that reduces the degrees of freedom of the ue and trunk, enables greater recovery of the movement of the ue and less use of compensatory movements compared to a protocol without dof control. the general objective is to demonstrate the effect of training with restriction of the degrees of freedom of ue and trunk, mediated by an exoskeleton and videogames, on the control of the ue.


Eligibility criteria:
inclusion criteria: * diagnosis of ischemic or hemorrhagic stroke with zero to six weeks of evolution. * subjects with alterations in active voluntary movement of es with fugl meyer less than or equal to 50 points. strength of shoulder abduction or finger extension from palpable contraction (1 in medical research council (mrc) scale for muscle strength). exclusion criteria: * cognitive impairment that prevents signing the informed consent, following the instructions and understanding the procedures. (moca \< 18). * inability to perform activities sitting for more than 90 minutes or inability to perform activities without severe pain (vas \> 6) or having limited reach ranges. * have severe visual impairment that does not allow to carry out the activities associated with the task. * previous stroke with neurological sequelae in the upper extremity. * present bilateral sensorimotor alterations. * damage to the cerebellum/peduncles described in the radiological report or classic signs of cerebellar damage (upper extremity sara items of 2 or more)

Keywords: stroke recovery motor recovery upper extremity recovery
interest of medical imaging in the diagnostic strategy vis a vis a suspected horton disease

Conditions: Horton Disease

Summary: the study aims at measuring the sensitivity and specificity of a series of imaging signs (recorded by magnetic resonance angiography, vascular tomodensitometry, vascular ultrasonography, retina angiography and retina optic coherence tomography) for the diagnosis of horton disease, the gold standard being the result of temporal artery biopsy.


Eligibility criteria:
inclusion criteria: * patients admitted to the fondation ophtalmologique adolphe de rothschild and suspected to suffer from horton disease, based on the presence of 3 or more major criteria, or 2 major criteria and at least one minor criteria. major criteria : age \> 50 ans ; headache ; intermittent jaw or tongue pain ; visual impairment ; esr \> 50 mm at 1h and/or crp \> 8mg/l. minor criteria: temporal artery or scalp tenderness ; facial pain or tenderness ; fever \>38°c, weight loss \>10%, anorexia, fatigue. exclusion criteria: * autoimmune disease * active infectious condition * malignant disease * condition counterindicating one or several of the protocol's imaging procedures : allergy to iodine and/or renal insufficiency and/or claustrophobia and/or metallic foreign body...
effects of volatile and intravenous anesthetics on pupillary function

Conditions: Pupillary Functions, Abnormal

Summary: to compare of effects of volatile and intravenous anesthetics on pupillary function during general anesthesia in children

the investigator will measure the pupillary function with pupillometry during general anesthesia with volatile or intravenous anesthetics in children.

Eligibility criteria:
inclusion criteria: * pediatric patients undergoing general anesthesia exclusion criteria: * if injection of any agents that can change pupil size or index * any severe side effects, adverse drug reaction
palpation versus taca- ultrasonography for identifying the cricothyroid membrane in case of a laterally deviated larynx

Conditions: Airway Management

Summary: test persons, anaesthesiologists will identify the cricothyroid membrane on a silicone model of the neck with either palpation or ultrasonography. the ultrasonographic method to be used is the thyroid-airline-cricoid-airline (taca) approach. the larynx-model is deviated to one of the sides to simulate a patient with neck pathology

test persons, anaesthesiologists will identify the cricothyroid membrane on a silicone model of the neck with either palpation or ultrasonography. the ultrasonographic method to be used is the thyroid-airline-cricoid-airline (taca) approach. the larynx-model is deviated to one of the sides to simulate a patient with neck pathology. the test persons are randomised to use other palpation or ultrasonography. al attempts are video-taped

Eligibility criteria:
inclusion criteria: participants in a course of airway management - exclusion criteria: exclusion criteria: unwillingness to participate -

Keywords: airway management, cricothyrotomy
hypercoagulable parameters as predictors of thrombotic events and prognosis in patients with advanced non-small cell lung carcinoma

Conditions: Non-Small Cell Lung Carcinoma; Venous Thromboembolism

Summary: the association between cancer and thrombosis is well known and the occurrence of thrombotic complications is commonly associated with poor prognosis. the aim os this study is to determine the possible value of hypercoagulable parameters as prognostic parameters in advanced non-small cell lung carcinoma (nsclc).


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed diagnosis of nsclc. * normal serum bilirubin * informed concent to participate in the study exclusion criteria: * anticoagulant therapy * infectious disease

Keywords: lung cancer thrombosis hypercoagulable
humoral immunodeficiency in cll and therapy with subcutaneous ig

Conditions: Secondary Immune Deficiency Disorder

Summary: patients with chronic lymphocytic leukemia (cll) are at increased risk of infections as compared to age matched controls, with infections being a major cause of morbidity and mortality. previous studies have shown that patients with cll have both hypogammaglobinemia and impaired humoral immunity as defined by vaccine responses to both polysaccharide and peptide antigens. attempts at decreasing infections in cll have included therapy with prophylactic antibiotics and intravenous immunoglobulin. in general clinical practice and in previous studies, patients have started iv immunoglobulin replacement therapy if they have a history of serious infection or hypogammaglobinemia (defined as immunoglobulin g below 500-600 g/dl), but vaccine responses have not been evaluated. this study will identify cll patients with humoral immunodeficiency by checking both ig levels and vaccines responses. in patients with impaired humoral immunity, the investigators will use subcutaneous immunoglobulin replacement to show this intervention will increase ig levels, protective antibody titers, and be well tolerated.


Eligibility criteria:
inclusion criteria: * diagnosis of chronic lymphocytic leukemia * medically stable, with expected survival of \> 1 year * able to understand and willingness to sign a written informed consent * able to comply with study procedures exclusion criteria: * previously diagnosed primary immunodeficiency * additional immunosuppressive states as assessed by the primary or co investigators * ongoing therapy with ig replacement * serum igg \< 500 mg/dl

Keywords: chronic lymphocytic leukemia
digital health intervention based on artificial intelligence to support the personalized recovery of long covid patients affected by fatigue (aida)

Conditions: Post Acute COVID-19 Syndrome

Summary: the aida feasibility study builds upon mental health and technology acceptance theoretical frameworks. it examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue. the program adhera ® fatigue self-management is adapted for long covid patients.

the study will explore the usability and engagement of a digital program designed for long covid patients affected by fatigue. the digital program relies on the adhera® personalized digital health solution that includes personalized patient education and support, monitoring using psychometrics and wearables, and mental wellbeing exercises. the patients access the mobile solution via a mobile app. a total of 15 patients will be recruited and use the mobile solution for one month.

Eligibility criteria:
inclusion criteria: * legal adults (older than 18) * long covid diagnosis within the last year * in possession of a compatible smartphone (android os v4.4 or higher) * reporting any of these symptoms: * fatigue * dyspnea * anxiety * stress * depression * sleep disorder exclusion criteria: * hospital admission during follow-up due to pathology not related to covid-19 * patients without digital literacy or who cannot use the mobile application. * known severe psychiatric illness or cognitive impairment * being pregnant (or suspected to be pregnant)

Keywords: long covid mhealth digital health emotional health behavioral intervention mental wellbeing mood disturbance emotional adjustment
glucose tolerance in children with cystic fibrosis

Conditions: Glucose Intolerance; Cystic Fibrosis

Summary: the aim is to describe the association of glucose tolerance measured with three different tools (continuous glucose measurement system - cgms, oral glucose tolerance testing - ogtt and optional intravenous glucose tolerance testing -ivgtt) with parameters out of lung function and anthropometric parameters in patients with cystic fibrosis.

patients with cystic fibrosis (cf) with progressing disease are developing a glucose tolerance which resembles the metabolic state of a diabetic patient because of increasing impairment of endocrine pancreatic function. the prevalence of this diabetic metabolic state is increasing with age, reaching around 20% at the age of 20 years. over the last decade, research has already highlighted the negative influence of cystic fibrosis related diabetes (cfrd) on morbidity and mortality after the diagnosis of this condition. as the deterioration in nutritional status and lung function can already be noticed 2-6 years before the onset of cfrd, the importance of early diagnosis in glucose abnormalities and its treatment therefore is crucial. the currently used method to evaluate altered glucose metabolism in patients with cf is an annual oral glucose tolerance test (ogtt) with the glucose value after 120 min after oral ingestion of glucose-fluid as reference. this method may detect cfrd much later than we see deterioration of lung function and weight loss. this deterioration and the mortality in cf is related to cfrd. an alternative diagnostic tool that has gained increasing attention and that is already routinely used in pediatric patients with diabetes mellitus type i is the continuous glucose monitoring system (cgms) which was shown to be much more sensitive in detecting glucose abnormalities. to assess pancreatic endocrine dysfunction - the pathophysiologic cause for glucose intolerance - intravenous glucose tolerance testing (ivgtt) is the gold standard. the investigator's aim is to describe the association of glucose tolerance measured with three different tools/assessment procedures (cgms, ogtt and optional ivgtt) with lung function and anthropometric parameters.

Eligibility criteria:
inclusion criteria: * patients with confirmed cystic fibrosis aged between 10-20 years, under medical treatment at the university children's hospital basel ukbb and at the university children's hospital, inselspital bern exclusion criteria: * patients being under medical treatment with systemically administered glucocorticoid drugs or intravenously administered antibiotic treatment within 6 weeks before glucose tolerance testing. * patients with acute pulmonary exacerbation, defined by a pediatric pneumologist

Keywords: children cystic fibrosis glucose intolerance continuous glucose measurement
pharmacokinetics of antiretroviral agents in hiv-infected pregnant women.

Conditions: HIV Infections

Summary: due to the potential for pregnancy-induced changes in the pharmacokinetics of medication, one cannot assume that the currently licensed doses of the medication to be tested under this protocol lead to adequate exposure in an hiv-infected pregnant woman. for the agents under study no or limited pharmacokinetic data during pregnancy are available. as the changes in pharmacokinetics during pregnancy are most prominent in the third trimester a pharmacokinetic curve will be recorded in the third trimester after attaining steady state.

the following agents will be studied: etravirine, intelence, tmc125; emtricitabine, emtriva or ftc; tenofovir, viread, tdf; atazanavir, reyataz; fosamprenavir, telzir, fpv; darunavir, prezista, tmc114; tipranavir, aptivus, tpv; indinavir, crixivan; abacavir; raltegravir, isentress; enfuvirtide, fuzeon; maraviroc, celsentri; dolutegravir; elvitegravir/cobicistat; rilpivirine, taf, darunavir/cobicistat; doravirine; bictegravir; cabotegravir/rilpivirine long acting injectables

Eligibility criteria:
inclusion criteria: 1. hiv-infected as documented by positive hiv antibody test and confirmed by an antigen test. 2. subject is at least 18 years of age at screening. 3. subject is able and willing to sign the informed consent form prior to screening evaluations. 4. treated with a cart regimen containing at least one agent which is mentioned in appendix 1; this agent has been taken for at least 2 weeks before the day of first pk curve evaluation. 5. subject is pregnant 6. subject is able to adhere to food intake recommendations, if applicable. exclusion criteria: 1. relevant history or current condition that might interfere with drug absorption, distribution, metabolism or excretion. 2. inability to understand the nature and extent of the study and the procedures required. 3. presence of grade iii/iv anemia (i.e. hb \<4.6 mmol/l or \<7.4 g/dl). 4. using oral cabotegravir/rilpivirine.

Keywords: pharmacokinetics pregnancy antiretrovirals neonates hiv treatment experienced
luna-emg to enhance motor functions in neurological disorders

Conditions: Stroke

Summary: the aim of the present study is to evaluate the effects of training performed with the luna-emg system to enhance motor functions of the upper limb in stroke this is a randomized open-label trial. patients will be randomized into the intervention group (luna-emg) or in the control group (standard care). the effect of the training will be measured with the emg, the upper limb motor function and the quality of life.


Eligibility criteria:
inclusion criteria: * adult * having signed the informed consent exclusion criteria: * acute pain syndrome * severe cognitive deficits * risk of fracture or unconsolidated fracture * rigid joints (spasticity, severe osteoarthritis and arthritis) or unstable joints * severe ataxia and apraxia * epilepsy * pacemakers and similar implants * insufficient skin conditions

Keywords: stroke emg rehabilitation physiotherapy occupational therapy
impact of cardiac complications on outcomes of patients after subarachnoid hemorrhage

Conditions: Subarachnoid Hemorrhage

Summary: patients with subarachnoid haemorrhage frequently develop cardiac complications affecting their outcome


Eligibility criteria:
inclusion criteria: * patients diagnosed as spontaneous subarachnoid hemorrhage. * ssah patients aged (18-70 years) of both sexes exclusion criteria: * history or current evidence of any cns disease other than sah which may cause cardiac complications. * history or current evidence of medical illness as endocrinal and metabolic disorders which may cause cardiac complications
adrenal suppression and adrenal recovery induced by megestrol acetate

Conditions: Adrenal Insufficiency

Summary: megestrol acetate (ma) is a progesterone-like hormone that has been utilized as a birth control agent, chemotherapeutic drug, and more recently, to induce appetite and weight gain in patients malnourished as a result of radiation therapy, chemotherapy, cystic fibrosis, aids, or dementia. the mechanism of ma-stimulated appetite and weight gain is unknown. although only approved to combat weight loss associated with aids and cancer, ma is frequently prescribed for long periods of time to prevent or reverse weight loss in nursing home residents and in elderly patients with serious illnesses in the community. little data is available to support this practice. among its many properties, ma acts as a partial glucocorticoid agonist, and long term and short term use of ma may results in adrenal suppression. the rapidity of the onset of ma-induced adrenal suppression and the time course of resumption of normal adrenal function after discontinuation of ma is completely unknown. as a consequence, it is unclear whether ma can be given safely for short periods of time or whether glucocorticoid administration is necessary after abruptly stopping ma treatment. the increased use of ma in the frail elderly, where even partial adrenal insufficiency may pose a substantial risk of adrenal crisis after an illness, requires a clear understanding of these issues. to address these concerns, we will evaluate adrenal function before, during, and after ma administration in healthy volunteers between the ages of 60 and 85 years.


Eligibility criteria:
inclusion criteria: * elderly males and females * age 65-80 years * with stable (no history of urgent/ emergent care visits with health care provider/s in the preceding 2 months), medical conditions exclusion criteria: subjects will be excluded if they have a history of (h/o): * dementia * adrenal disease * thromboembolism * diabetes mellitus * liver disease * electrolyte abnormalities; or * vaginal bleeding * hypertriglyceridemia * cad with chf * unstable depression * schizophrenia; and * morbidly obese subjects.

Keywords: megestrol acetate adrenal insufficiency adrenal suppression
metabolic determinants of resting energy expenditure among mechanically ventilated critically ill patients

Conditions: Critical Illness

Summary: currently there are no study related to indirect calorimetry (ic) has been done among hospitalised malaysian icu adult patients with its racial mix. the aim of this study is to perform a cross-sectional study in malaysian critically ill patients to determine metabolic determinants that might influence resting energy expenditure (ree) and to develop predictive equation for the estimation of energy requirement using the regression based approach to increase the accuracy in calorie prescriptions. in addition, expected outcome of this study is to determine which equations have clinical usefulness among malaysian adult critically ill patients and hope to introduce into routine clinical practice in the future if ic is not available.

nutrition provision in the clinical setting relies heavily on the accurate estimation of energy and protein requirements. this can be done in a quick and inexpensive manner via the use of predictive equations. some of the most popularly used predictive equations such as the harris-benedict equation and the mifflin-st. jeor equation have been widely applied within the clinical setting to estimate energy requirements among mechanically ventilated critically ill patients. however, these existing equations were not specially developed for a population with disease, as the equations were derived from a pool of healthy caucasian adults. in addition, most of the equations for critically ill patients such as the penn state equation, faisy equation and raurich equation developed and validated among caucasian in western country and not among asian population. therefore, their accuracy in predicting energy requirement is questionable when applied within malaysian mechanically ventilated critically ill patients with its racial mix.

Eligibility criteria:
inclusion criteria: 1. adult patients aged over 18 years old 2. critically ill patients with mechanically ventilated 3. expected to have an icu stay of more than 5 days 4. patients had implemented for continuous enteral or parenteral nutrition support. exclusion criteria: 1. requirement for inspired oxygen content (fio2) greater than 0.6 2. patients on high frequency ventilation 3. patients with chest tubes that leak air 4. patients with incompetent tracheal cuff 5. patients inhaled nitric oxide therapy 6. patients receiving intermittent hemodialysis and continuous renal replacement therapy (crrt) during ic measurement 7. patients with pregnancy 8. patients with burn injury 9. patients infected with human immunodeficiency virus (hiv) 10. patients with severe liver disease (child-pugh score c) 11. patients with post open heart surgery 12. patients with paraplegia and quadriplegia